Document Detail

Different schedules of granulocyte growth factor support for patients with breast cancer receiving adjuvant dose-dense chemotherapy: a prospective nonrandomized study.
MedLine Citation:
PMID:  21217400     Owner:  NLM     Status:  MEDLINE    
PURPOSE: This prospective, nonrandomized study evaluates 4 schedules of granulocyte colony-stimulating factor (G-CSF) for patients with breast cancer receiving adjuvant dose-dense chemotherapy regarding febrile neutropenia, treatment delays, and costs.
PATIENTS AND METHODS: Two hundred and thirty-one patients were enrolled to receive adjuvant dose-dense chemotherapy with 4 G-CSF schedules: filgrastim (300 mcg) days 3 to 10 [n = 84 (36.4%) group A]; days 3 to 7 [n = 26 (11.3%) group B]; days 5, 7, 9, and 11 [n = 64 (27.7%) group C], or pegfilgrastim (6 mg) on day 2 [n=57 (24.6%) group D].
RESULTS: Thirteen patients were hospitalized due to 14 episodes of febrile neutropenia; 3 in group A, 3 in group B, 1 in group C, and 6 in group D. No statistically significant difference was observed among the 4 groups. Fewer febrile neutropenic events were observed in group C than in group D (P=0.041). No statistically significant differences were observed in treatment delays or other hematological toxicities. Average overall G-CSF cost per patient in groups A and D was $8500 versus $4400 in groups B and C.
CONCLUSIONS: We found a trend in favor of the shorter G-CSF schedule. A larger, prospective randomized trial should be carried out to evaluate shorter versus standard filgrastim and pegfilgrastim schedules with regard to clinical outcomes, hematological and nonhematological toxicities, and impact in costs.
Daniel Hendler; Shulamith Rizel; Rinat Yerushalmi; Victoria Neiman; Luisa Bonilla; Rony Braunstein; Aaron Sulkes; Salomon M Stemmer
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of clinical oncology     Volume:  34     ISSN:  1537-453X     ISO Abbreviation:  Am. J. Clin. Oncol.     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-11-22     Completed Date:  2012-01-03     Revised Date:  2012-07-05    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  619-24     Citation Subset:  IM    
Institute of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Breast Neoplasms* / drug therapy
Chemotherapy, Adjuvant / adverse effects
Granulocyte Colony-Stimulating Factor / administration & dosage*,  economics
Middle Aged
Neutropenia / chemically induced,  drug therapy*,  economics
Recombinant Proteins / administration & dosage,  economics
Reg. No./Substance:
0/Recombinant Proteins; 0/pegfilgrastim; 121181-53-1/Filgrastim; 143011-72-7/Granulocyte Colony-Stimulating Factor
Comment In:
Am J Clin Oncol. 2012 Jun;35(3):307   [PMID:  22609734 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Trends in Colorectal Cancer Incidence by Anatomic Site and Disease Stage in the United States From 1...
Next Document:  The effects of napping on cognitive function in preschoolers.